Avicenna Pharmaceuticals is utilizing the proprietary NOSH technology platform to develop Enhanced Non-Steroidal Anti-inflammatory Drugs. eNSAIDs are anticipated to have a broader range of activity compared to conventional NSAIDs, while having a significantly improved safety profile...
eNSAIDs are designed to release two key short lived biologically active gases, nitric oxide and hydrogen sulfide. These gases compensate for NSAID induced low prostaglandin levels and increase mucosal blood flow and mucosal repair.